1. Home
  2. CERO vs GLTO Comparison

CERO vs GLTO Comparison

Compare CERO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • GLTO
  • Stock Information
  • Founded
  • CERO 2017
  • GLTO 2011
  • Country
  • CERO United States
  • GLTO Denmark
  • Employees
  • CERO N/A
  • GLTO N/A
  • Industry
  • CERO
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERO
  • GLTO Health Care
  • Exchange
  • CERO Nasdaq
  • GLTO Nasdaq
  • Market Cap
  • CERO 8.4M
  • GLTO 6.5M
  • IPO Year
  • CERO N/A
  • GLTO 2020
  • Fundamental
  • Price
  • CERO $2.06
  • GLTO $4.78
  • Analyst Decision
  • CERO
  • GLTO Buy
  • Analyst Count
  • CERO 0
  • GLTO 1
  • Target Price
  • CERO N/A
  • GLTO $10.00
  • AVG Volume (30 Days)
  • CERO 725.7K
  • GLTO 20.8K
  • Earning Date
  • CERO 02-24-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • CERO N/A
  • GLTO N/A
  • EPS Growth
  • CERO N/A
  • GLTO N/A
  • EPS
  • CERO N/A
  • GLTO N/A
  • Revenue
  • CERO N/A
  • GLTO N/A
  • Revenue This Year
  • CERO N/A
  • GLTO N/A
  • Revenue Next Year
  • CERO N/A
  • GLTO N/A
  • P/E Ratio
  • CERO N/A
  • GLTO N/A
  • Revenue Growth
  • CERO N/A
  • GLTO N/A
  • 52 Week Low
  • CERO $1.70
  • GLTO $4.24
  • 52 Week High
  • CERO $1,095.00
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • CERO 37.15
  • GLTO 45.49
  • Support Level
  • CERO $1.70
  • GLTO $4.24
  • Resistance Level
  • CERO $2.22
  • GLTO $4.65
  • Average True Range (ATR)
  • CERO 0.30
  • GLTO 0.33
  • MACD
  • CERO 0.27
  • GLTO -0.02
  • Stochastic Oscillator
  • CERO 24.32
  • GLTO 43.25

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: